AtaiBeckley Inc. ATAI
Founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage biotechnology company on a mission to create breakthroughs for people with difficult-to-treat mental health conditions. Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve.
Mental health disorders are highly prevalent and estimated to affect more than one billion people globally. The economic burden of these disorders is substantial and is growing rapidly. Between 2009 and 2019, spending on mental health care in the United States increased by more than 50%, reaching $225.0 billion, and a Lancet Commission report estimates that the global economic cost will reach $16.0 trillion by 2030. While current treatments, such as selective serotonin reuptake inhibitors ("SSRIs") and serotonin-norepinephrine reuptake inhibitors ("SNRIs") are well established and effective for certain patients, approximately 65% of patients do not achieve remission of their symptoms after up to four antidepressant treatment trials, translating to a significant unmet medical need.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $4.1M | $308.0K | — |
| R&D | — | $900.0K | — |
| SG&A | $65.1M | $47.5M | — |
| Total operating expenses | $648.1M | $103.0M | — |
| Operating income | -$644.1M | -$102.7M | — |
| Interest expense | $1.2M | $3.1M | — |
| Pre-tax income | -$659.8M | -$148.4M | — |
| Income tax | $298.0K | $356.0K | — |
| Net income | -$660.0M | -$149.3M | — |
| EPS, basic | -2.91 | -0.93 | — |
| EPS, diluted | -2.91 | -0.93 | — |
| Shares, diluted (wtd. avg.) | 226.5M | 160.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $85.3M | $17.5M | $45.0M |
| Receivables | $667.0K | $354.0K | — |
| Total current assets | $275.7M | $80.1M | — |
| Property, plant and equipment | $2.2M | $2.5M | — |
| Goodwill | $331.0K | $331.0K | — |
| Other intangibles | $2.9M | $3.2M | — |
| Total assets | $292.7M | $159.4M | — |
| Accounts payable | $4.9M | $2.6M | — |
| Short-term debt | $135.4M | $6.4M | — |
| Total current liabilities | $23.5M | $25.0M | — |
| Long-term debt | $0 | $14.1M | — |
| Total liabilities | $70.7M | $42.8M | — |
| Retained earnings | -$1.36B | -$700.2M | — |
| Total equity | $221.9M | $116.3M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$102.7M | -$82.4M | — |
| Depreciation and amortisation | $1.0M | $473.0K | — |
| Stock-based compensation | $14.2M | $25.5M | — |
| Capital expenditure | $901.0K | $6.0K | — |
| Investing cash flow | -$109.1M | $59.2M | — |
| Financing cash flow | $269.5M | $5.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-096926.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $308.0K | $4.1M |
| Gross profit | — | — | — |
| Net income | — | -$149.3M | -$660.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |